Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of “Buy” by Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given a consensus rating of “Buy” by the five research firms that are presently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last year is $19.80.

Several analysts have recently issued reports on IRWD shares. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. Piper Sandler upped their target price on shares of Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Craig Hallum assumed coverage on shares of Ironwood Pharmaceuticals in a research note on Wednesday, January 17th. They issued a “buy” rating and a $21.00 target price for the company. Finally, Wells Fargo & Company reduced their price target on shares of Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, March 1st.

Ironwood Pharmaceuticals Stock Down 0.2 %

Ironwood Pharmaceuticals stock opened at $8.08 on Friday. Ironwood Pharmaceuticals has a 12-month low of $7.53 and a 12-month high of $15.70. The firm’s fifty day moving average is $9.64 and its 200 day moving average is $10.66. The company has a market capitalization of $1.26 billion, a PE ratio of -1.24 and a beta of 0.55.

Insider Transactions at Ironwood Pharmaceuticals

In related news, Director Jon R. Duane purchased 6,920 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were acquired at an average price of $8.70 per share, for a total transaction of $60,204.00. Following the completion of the acquisition, the director now directly owns 121,028 shares in the company, valued at approximately $1,052,943.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Andrew Davis sold 9,846 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $15.24, for a total value of $150,053.04. Following the completion of the transaction, the senior vice president now owns 208,324 shares of the company’s stock, valued at approximately $3,174,857.76. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jon R. Duane purchased 6,920 shares of the stock in a transaction dated Wednesday, March 6th. The stock was bought at an average cost of $8.70 per share, with a total value of $60,204.00. Following the transaction, the director now owns 121,028 shares in the company, valued at $1,052,943.60. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 273,008 shares of company stock worth $4,160,642. Insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Large investors have recently made changes to their positions in the company. Signaturefd LLC lifted its holdings in Ironwood Pharmaceuticals by 61.4% in the 4th quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 822 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in Ironwood Pharmaceuticals by 331.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,473 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,900 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Ironwood Pharmaceuticals by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,997 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,961 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Ironwood Pharmaceuticals by 152.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 2,645 shares in the last quarter. Finally, Headlands Technologies LLC increased its position in shares of Ironwood Pharmaceuticals by 396.5% in the third quarter. Headlands Technologies LLC now owns 6,737 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 5,380 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.